HealthDay News — Preoperative metformin prescriptions may be associated with decreased postoperative mortality and readmission among patients with diabetes undergoing a major surgical procedure, according to a study published online April 8 in JAMA Surgery.
Katherine M. Reitz, MD, from the University of Pittsburgh School of Medicine, and colleagues used electronic health record data to identify 10,088 adults with diabetes who underwent a major operation with hospital admission (January 2010 to January 2016) at 15 community and academic hospitals within one health care system. Fifty-nine percent had preoperative metformin prescriptions. The analysis included 5460 propensity score-matched patients (mean age, 67.7 years; 53% women).
The researchers found that in the propensity score-matched cohort, preoperative metformin was associated with a reduced hazard for 90-day mortality (adjusted hazard ratio [HR], 0.72 [95% confidence interval (CI), 0.55 to 0.95]; absolute risk reduction [ARR], 1.28% [95% CI, 0.26 to 2.31]) and hazard of readmission at 30 days (ARR, 2.09% [95% CI, 0.35 to 3.82]; sub-HR, 0.84 [95% CI, 0.72 to 0.98]) and 90 days (ARR, 2.78% [95% CI, 0.62 to 4.95]; sub-HR, 0.86 [95% CI, 0.77 to 0.97]). Preoperative inflammation was lower in those with metformin prescriptions vs those without (mean neutrophil-to-leukocyte ratio, 4.5 [95% CI, 4.3 to 4.6] vs 5.0 [95% CI, 4.8 to 5.3]).
“The advantages are likely not disease specific, but instead the pleiotropic properties may modulate the stress response generated by a major surgical intervention or confer consistently good outcomes, regardless of the surgical procedure,” the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.